


The Fund's objective is to produce a high and rising income.
| Name | % Net Assets |
|---|---|
| Total | 4.7% |
| Sanofi-Aventis | 4.0% |
| ENI | 3.9% |
| Roche | 3.6% |
| OPAP | 3.5% |
| Vivendi Universal | 3.5% |
| Nestlé | 3.2% |
| Telefonica | 3.0% |
| Nokia | 2.9% |
| Novartis | 2.7% |
| Key | % Net Assets |
|---|---|
| 4.7% | |
| 4.0% | |
| 3.9% | |
| 3.6% | |
| 83.8% |
| Date | 08-Nov-2022 |
|---|---|
| NAV | 85.02p |
| Currency | GBP |
| Change | 0.004p |
| % | n/a |
| YTD change | 85.02p |
| YTD % | n/a |
| Fund Inception | 08/05/2007 |
|---|---|
| Fund Manager | Malcolm Millar |
| TER | 1.81 (31-Oct-2013) |
| Minimum Investment | |
|---|---|
| Initial | £500 |
| Additional | n/a |
| Savings | £100 |
| Charges | |
|---|---|
| Initial | 5.25% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research